<DOC>
	<DOCNO>NCT01047566</DOCNO>
	<brief_summary>The primary objective study : Assess whether addition dronedarone exist conventional rate control therapy lead reduce ventricular rate 1 week patient high Heart Rate ( HR ) rest Atrial Fibrillation ( AF ) comparison increase conventional therapy . The secondary objective study compare study arm regard : - Ventricular rate 3 month - Number register AF episodes - Number symptomatic AF episodes - Severity AF AF-like symptom - Rate premature study discontinuation - Number symptomatic episode bradycardia - Incidence low heart rate ( &lt; 60 bpm )</brief_summary>
	<brief_title>Effect Addition Dronedarone Standard Rate Control Therapy Ventricular Rate During Persistent Atrial Fibrillation ( AFRODITE )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Persistent AF HR &gt; 80 bpm rest despite treatment ≤ 2 rate control agent ( i.e . beta blocker and/or calcium antagonist Patients use digoxin eligible ) Documented AF past 24 hour Treated follow rate control medication : beta blocker calcium antagonist beta blocker plus calcium antagonist beta blocker plus digoxin calcium antagonist plus digoxin Anticoagulant treatment line local guideline Incapacitated patient Paroxysmal permanent AF Use class I III antiarrhythmic drug past 12 week Scheduled cardioversion pulmonary vein ablation Unstable New York Heart Association ( NYHA ) class III class IV Heart Failure AV block grade 2 3 Known severe renal impairment ( serum creatinine &gt; 180 μmol/l ) Known severe hepatic impairment ( AST , ALT &gt; 3 x Upper Limit Normal ( ULN ) ) Contraindication dronedarone Participation clinical drug study 3 month prior inclusion Women childbearing potential , use adequate contraception Lactating woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>